Patents by Inventor George Doherty

George Doherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS
    Publication number: 20110118235
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.
    Type: Application
    Filed: August 18, 2010
    Publication date: May 19, 2011
    Applicants: VentiRx Pharmaceuticals, Inc., Array BioPharma, Inc.
    Inventors: James Jeffry Howbert, Gregory Dietsch, Robert Hershberg, Laurence E. Burgess, George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES
    Publication number: 20110105463
    Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    Type: Application
    Filed: June 24, 2009
    Publication date: May 5, 2011
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Laurence E. Burgess, Christopher T. Clark, Adam Cook, Christopher P. Corrette, Robert Kirk DeLisle, George A. Doherty, Kevin W. Hunt, Todd T. Romoff
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20100305122
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: May 26, 2010
    Publication date: December 2, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert A. Mantei, Todd M. Hansen
  • BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
    Publication number: 20100298321
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: June 3, 2010
    Publication date: November 25, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Todd M. Hansen
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20100298323
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: June 3, 2010
    Publication date: November 25, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Milan Bruncko, Yujia Dai, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron R. Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Todd M. Hansen
  • 4-HETEROARYL-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES
    Publication number: 20100273850
    Abstract: Compounds of Formula I: I in which D1, D2, R1, R2, R7, R8 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    Type: Application
    Filed: November 4, 2008
    Publication date: October 28, 2010
    Inventor: George A. Doherty
  • 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES
    Publication number: 20100173955
    Abstract: Compounds of Formula (I): in which R1, R2, R7, R8, R9, R10 and A have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
    Type: Application
    Filed: August 21, 2007
    Publication date: July 8, 2010
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: George Doherty, Adam Cook
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20100160322
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: December 4, 2009
    Publication date: June 24, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Milan Bruncko, Yujia Dai, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
    Publication number: 20100152183
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: December 4, 2009
    Publication date: June 17, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa Hasvold, Laura Hexamer, Aaron Kunzer, Robert A. Mantei, William J. McClellan, Chang H. Park, Cheol-Min Park, Andrew M. Petros, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt
  • NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20100093730
    Abstract: The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Application
    Filed: October 1, 2009
    Publication date: April 15, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Pramila A. Bhatia, George A. Doherty, Irene Drizin, Helmut Mack, Richard J. Perner, Andrew O. Stewart, Qingwei Zhang
  • MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
    Publication number: 20090286843
    Abstract: The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: October 20, 2008
    Publication date: November 19, 2009
    Inventors: LAWRENCE M. BLATT, STEVEN W. ANDREWS, KEVIN R. CONDROSKI, GEORGE A. DOHERTY, YUTONG JIANG, JOHN A. JOSEY, APRIL L. KENNEDY, MACHENDER R. MADDURU, PETER J. STENGEL, STEVEN M. WENGLOWSKY, BENJAMIN T. WOODARD, LAURA WOODARD
  • (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
    Patent number: 7605171
    Abstract: The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 20, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Vincent J. Colandrea, George A. Doherty, Jeffrey J. Hale, Pei Huo, Irene E. Legiec, Leslie Toth, Petr Vachal, Lin Yan
  • MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
    Publication number: 20090111969
    Abstract: The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: December 22, 2008
    Publication date: April 30, 2009
    Inventors: Lawrence M. Blatt, Steven W. Andrews, Kevin R. Condroski, George A. Doherty, Yutong Jiang, John A. Josey, April L. Kennedy, Machender R. Madduru, Peter J. Stengel, Steven M. Wenglowsky, Benjamin T. Woodard, Laura Woodard
  • MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
    Publication number: 20090111982
    Abstract: The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: December 22, 2008
    Publication date: April 30, 2009
    Inventors: Lawrence M. Blatt, Steven W. Andrews, Kevin R. Condroski, George A. Doherty, Yutong Jiang, John A. Josey, April L. Kennedy, Machender R. Madduru, Peter J. Stengel, Steven M. Wenglowsky, Benjamin T. Woodard, Laura Woodard
  • MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
    Publication number: 20090105471
    Abstract: The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    Type: Application
    Filed: December 22, 2008
    Publication date: April 23, 2009
    Inventors: Lawrence M. Blatt, Steven W. Andrews, Kevin R. Condroski, George A. Doherty, Yutong Jiang, John A. Josey, April L. Kennedy, Machender R. Madduru, Peter J. Stengel, Steven M. Wenglowsky, Benjamin T. Woodard, Laura Woodard
  • Edg receptor agonists
    Patent number: 7479504
    Abstract: The present invention encompasses compounds of Formula 1: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Grant
    Filed: January 15, 2003
    Date of Patent: January 20, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Robert L. Bugianesi, George A. Doherty, Amy Gentry, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
  • Aminodiazepines as Toll-Like Receptor Modulators
    Publication number: 20080306050
    Abstract: Provided are compositions and methods useful for modulation signaling through the Toll-like receptor TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Application
    Filed: August 17, 2006
    Publication date: December 11, 2008
    Inventors: George A. Doherty, Zachary Jones
  • (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists
    Publication number: 20080249093
    Abstract: The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.
    Type: Application
    Filed: December 13, 2004
    Publication date: October 9, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Vincent J. Colandrea, George A. Doherty, Jeffrey J. Hale, Pei Huo, Irene E. Legiec, Leslie Toth, Petr Vachal, Lin Yan
  • 8-Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20080234251
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Application
    Filed: August 17, 2006
    Publication date: September 25, 2008
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
    Patent number: 7351725
    Abstract: The present invention encompasses compounds of Formula (I) as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: April 1, 2008
    Assignee: Merck & Co., Inc.
    Inventors: George A. Doherty, Zhen Li, Jeffrey J. Hale, Sander G. Mills